An interventional study of Pressure Support Ventilation (PSV) and Automatic tube compensation (ATC) in Spontaneous Breathing Trial in ICU, sponsored by Rush University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Rush University Medical Center · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
For patients requiring mechanical ventilation, spontaneous breathing trials (SBTs) are conducted to determine if it is safe to remove the breathing tube. There are multiple methods for conducting SBTs. The purpose of this study is to compare the effects of 2 methods, pressure support ventilation (PSV) versus automatic tube compensation (ATC), on successful extubation for critically ill adult patients who received mechanical ventilation for over 24 hours.
The delivery of pressure support through the ventilator can be fixed using the pressure support ventilation (PSV) mode or variable using the automatic tube compensation (ATC) mode. Similar to PSV, ATC provides pressure support but dynamically adjusts it to compensate the resistive work of breathing and the mechanical load on respiratory muscles imposed by an artificial airway, such as an endotracheal or tracheostomy tube. Although both ATC and PSV are licensed and used in clinical practice, the optimal method to deliver pressure support during a spontaneous breathing trial (SBT) remains unknown. At Rush University Medical Center, ATC has been used for SBTs for over a decade. However, given the growing popularity of PSV, the SBT protocol was updated and now approves the use of PSV and ATC as standard care for SBT without making a recommendation for a preferred mode. The choice between PSV and ATC during SBT is left to the discretion of the clinician, reflecting the ongoing equipoise in the conduct of the SBT. As patients will be exposed to the potential benefits and risks of PSV or ATC under this change in clinical practice, the investigators are conducting a cluster-randomized cluster-crossover trial to compare the mode's effect on successful extubation.
Rush University Medical Center is the lead sponsor of 397 studies on the registry; 60 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Pressure Support Ventilation (PSV) · Other: Automatic tube compensation (ATC)
Other: Pressure Support Ventilation (PSV) · Other: Automatic tube compensation (ATC)
Other: Pressure Support Ventilation (PSV) · Other: Automatic tube compensation (ATC)
Other: Pressure Support Ventilation (PSV) · Other: Automatic tube compensation (ATC)
Spontaneous breathing trials will be conducted using the mode pressure support ventilation (PSV) with settings of a pressure support of 5 cmH2O and positive end expiratory pressure (PEEP) 5 cmH2O.
Spontaneous breathing trials will be conducted using the mode automatic tube compensation (ATC) with settings of 100% tube compensation and a positive end expiratory pressure (PEEP) of 5 cmH2O.
Reintubation, continued invasive mechanical ventilation, or death
Time frame: 48 hours after receiving the first SBT
Time to successful extubation
The duration (in hours) from the first spontaneous breathing trial (SBT) initiation to extubation without reintubation within 48 hours
Time frame: From the start of the first spontaneous breathing trial (SBT) to the first successful extubation (without reintubation within 48 hours) or death from any cause, whichever occurred first, assessed up to 30 days.
Ventilator-free days
The number of days without mechanical ventilation after enrollment and up to 28 days
Time frame: From study enrollment to 28 days after enrollment
ICU free days, censored at day 28
The number of days out of the ICU after enrollment and up to 28 days
Time frame: From study enrollment to 28 days after enrollment
Hospital free days
The number of days out of the hospital after enrollment and up to 28 days
Time frame: From study enrollment to 28 days after enrollment
Spontaneous breathing trial (SBT) results
SBT results (pass or fail) for the first 3 attempts if conducted
Time frame: Up to 30 days from study enrollment or until hospital discharge, whichever occurs first
Reintubation
Time frame: Within 48 hours after extubation
Reintubation
Time frame: Within 7 days after extubation
Use of noninvasive respiratory support
Use of noninvasive ventilation, continuous positive airway pressure (CPAP), and high flow nasal cannula (HFNC) and its duration
Time frame: Within 48 hours of extubation
Total duration of mechanical ventilation
Time frame: From the date of intubation to the date of extubation or death from any cause, whichever occurs first, assessed up to 30 days
Intensive care unit (ICU) length of stay (LOS)
Time frame: From the date of ICU admission to the date of ICU discharge, assessed up to 30 days.
Hospital length of stay (LOS)
Time frame: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
Mortality
Time frame: At ICU discharge, censored at 28 days
Clinician adherence to initially assigned spontaneous breathing trial (SBT) mode
Time frame: Up to 30 days
Safety Events During SBT
Occurrence of pneumothroax, unintentional extubation, or unstable cardiac rhythm during the SBT
Time frame: From study enrollment to the date of extubation or death from any cause, whichever occurs first, assessed up to 30 days
Plan to share: No
Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rush University Medical Center →